Australia has expanded access to CSL Seqirus' influenza vaccine, FLUAD, with approval now extended to people aged 50 and over, a move health experts say reflects the growing risk of serious flu complications beginning in midlife.
CSL Seqirus' adjuvanted flu vaccine approval extended to Australians aged 50 and over
March 15, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Is this new parliamentary inquiry the latest example of a 'controlling' instinct?
November 23, 2026 - - Latest News -
Former Australian cricketer shares RSV experience as survey reveals gap in personal risk awareness
November 23, 2026 - - Latest News -
Australians unsure of cholesterol levels as campaign challenges heart health myths
November 23, 2026 - -
PBS talks begin under fiscal strains with patients, as always, left outside the room
November 23, 2026 - - Latest News -
While the PBS continues to fall short, we should expect more of these innovative alternatives
November 23, 2026 - - Latest News -
It happened last time, so it makes sense to start next week assuming it as the base case
November 20, 2026 - - Latest News -
Applying the principles of the Reserve Bank review to HTA advisory committees
November 20, 2026 - - Latest News

